|
[1]
|
Sebastiano, M.R., Pozzato, C., Saliakoura, M., et al. (2020) ACSL3-PAI-1 Signaling Axis Mediates Tumor-Stroma Cross-Talk Promoting Pancreatic Cancer Progression. Science Advances, 6, eabb9200. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Liu, L., Huang, X., Shi, F., et al. (2022) Combination Therapy for Pancreatic Cancer: Anti-PD-(L)1-Based Strategy. Journal of Experimental & Clinical Cancer Research, 41, Article No. 56. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Conroy, T., Hammel, P., Hebbar, M., et al. (2018) FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. New England Journal of Medicine, 379, 2395-2406. [Google Scholar] [CrossRef]
|
|
[4]
|
Bengtsson, A., Andersson, R. and Ansari, D. (2020) The Actual 5-Year Survivors of Pancreatic Ductal Adenocarcinoma Based on Real-World Data. Scientific Reports, 10, Article No. 16425. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Timmer, F.E.F., Geboers, B., Nieuwenhuizen, S., et al. (2021) Pancreatic Cancer and Immunotherapy: A Clinical Overview. Cancers, 13, Article No. 4138. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Huber, M., Brehm, C.U., Gress, T.M., et al. (2020) The Immune Microenvironment in Pancreatic Cancer. International Journal of Molecular Sciences, 21, Article No. 7307. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Chen, J., Guo, X.-Z. and Qi, X.-S. (2017) Clinical Outcomes of Spe-cific Immunotherapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. Journal of Immunology Research, 2017, Article ID: 8282391. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Principe, D.R., Korc, M., Kamath, S.D., Munshi, H.G. and Rana, A. (2021) Trials and Tribulations of Pancreatic Cancer Immunotherapy. Cancer Letters, 504, 1-14. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Bear, A.S., Vonderheide, R.H. and O’Hara, M .H. (2020) Chal-lenges and Opportunities for Pancreatic Cancer Immunotherapy. Cancer Cell, 38, 788-802. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Darvin, P., Toor, S.M., Sasidharan Nair, V. and Elkord, E. (2018) Immune Checkpoint Inhibitors: Recent Progress and Potential Biomarkers. Experimental & Molecular Medicine, 50, 1-11. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Khasraw, M., Reardon, D.A., Weller, M. and Sampson, J.H. (2020) PD-1 Inhibitors: Do They Have a Future in the Treatment of Glioblastoma? Clinical Cancer Research, 26, 5287-5296. [Google Scholar] [CrossRef]
|
|
[12]
|
Wei, S.C., Duffy, C.R. and Allison, J.P. (2018) Funda-mental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discovery, 8, 1069-1086. [Google Scholar] [CrossRef]
|
|
[13]
|
Ruiz-Bañobre, J. and Goel, A. (2019) DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers. Gastroenterology, 156, 890-903. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Henriksen, A., Dyhl-Polk, A., Chen, I. and Nielsen, D. (2019) Checkpoint Inhibitors in Pancreatic Cancer. Cancer Treatment Reviews, 78, 17-30. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Feng, M., Xiong, G., Cao, Z., et al. (2017) PD-1/PD-L1 and Im-munotherapy for Pancreatic Cancer. Cancer Letters, 407, 57-65. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Messenheimer, D.J., Jensen, S.M., Afentoulis, M.E., et al. (2017) Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40. Clinical Cancer Research, 23, 6165-6177. [Google Scholar] [CrossRef]
|
|
[17]
|
Mace, T.A., Shakya, R., Pitarresi, J.R., et al. (2018) IL-6 and PD-L1 Antibody Blockade Combination Therapy Reduces Tumour Progression in Murine Models of Pancreatic Cancer. Gut, 67, 320-332. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Gao, Y., Li, S., Xu, D., et al. (2017) Prognostic Value of Pro-grammed Death-1, Programmed Death-Ligand 1, Programmed Death-Ligand 2 Expression, and CD8(+) T Cell Density in Primary Tumors and Metastatic Lymph Nodes From Patients with Stage T1-4N + M0 Gastric Adenocarcinoma. Chinese Journal of Cancer, 36, Article No. 61. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Daley, D., Mani, V., Mohan, N., et al. (2017) Dectin 1 Activation on Macrophages by Galectin 9 Promotes Pancreatic Carcinoma and Peritumoral Immune Tolerance. Nature Medicine, 23, 556-567. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Lheureux, S., Butler, M.O., Clarke, B., et al. (2018) Association of Ipilimumab with Safety and Antitumor Activity in Women with Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma. JAMA Oncology, 4, e173776. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Huang, Y., Fan, H., Li, N. and Du, J. (2019) Risk of Im-mune-Related Pneumonitis for PD1/PD-L1 Inhibitors: Systematic Review and Network Meta-Analysis. Cancer Medicine, 8, 2664-2674. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Christenson, E.S., Jaffee, E. and Azad, N.S. (2020) Current and Emerging Therapies for Patients with Advanced Pancreatic Ductal Adenocarcinoma: A Bright Future. The Lancet Oncology, 21, e135-e145. [Google Scholar] [CrossRef]
|
|
[23]
|
Hingorani, S.R., Zheng, L., Bullock, A.J., et al. (2018) HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine versus Nab-Paclitaxel/Gemcitabine in Patients with Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. Journal of Clinical Oncology, 36, 359-366. [Google Scholar] [CrossRef]
|
|
[24]
|
Aglietta, M., Barone, C., Sawyer, M.B., et al. (2014) A Phase I Dose Escalation Trial of Tremelimumab (CP-675,206) in Combination with Gemcitabine in Chemotherapy-Naive Patients with Metastatic Pancreatic Cancer. Annals of Oncology, 25, 1750-1755. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Riley, R.S., June, C.H., Langer, R. and Mitchell, M.J. (2019) Delivery Technologies for Cancer Immunotherapy. Nature Reviews Drug Discovery, 18, 175-196. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Kartikasari, A.E.R., Prakash, M.D., Cox, M., et al. (2018) Ther-apeutic Cancer Vaccines-T Cell Responses and Epigenetic Modulation. Frontiers in Immunology, 9, Article 3109. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Brar, G., Greten, T.F. and Brown, Z.J. (2018) Current Frontline Approaches in the Management of Hepatocellular Carcinoma: The Evolving Role of Immunotherapy. Therapeutic Ad-vances in Gastroenterology, 11. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Soares, K.C., Rucki, A.A., Wu, A.A., et al. (1997) PD-1/PD-L1 Blockade Together with Vaccine Therapy Facilitates Effector T-Cell Infiltration into Pancreatic Tumors. Journal of Immunotherapy, 38, 1-11. [Google Scholar] [CrossRef]
|
|
[29]
|
Le, D.T., Lutz, E., Uram, J.N., et al. (1997) Evaluation of Ipilimumab in Combination with Allogeneic Pancreatic Tumor Cells Transfected with a GM-CSF Gene in Previously Treated Pancreatic Cancer. Journal of Immunotherapy, 36, 382-389. [Google Scholar] [CrossRef]
|
|
[30]
|
Coveler, A.L., Rossi, G.R., Vahanian, N.N., et al. (2016) Algenpantucel-L Immunotherapy in Pancreatic Adenocarcinoma. Immunotherapy, 8, 117-125.
|
|
[31]
|
Koido, S., Okamoto, M., Kobayashi, M., Shimodaira, S. and Sugiyama, H. (2017) Significance of Wilms’ Tumor 1 Antigen as a Cancer Vaccine for Pancreatic Cancer. Discovery Medicine, 24, 41-49.
|
|
[32]
|
Nishida, S., Koido, S., Takeda, Y., et al. (2014) Wilms Tumor Gene (WT1) Peptide-Based Cancer Vaccine Combined with Gemcitabine for Patients with Advanced Pancreatic Cancer. Journal of Immunotherapy, 37, 105-114. [Google Scholar] [CrossRef]
|
|
[33]
|
Rivadeneira, D.B. and Delgoffe, G.M. (2018) Antitumor T-Cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy. Clinical Cancer Research, 24, 2473-2481. [Google Scholar] [CrossRef]
|
|
[34]
|
Yamaue, H., Tsunoda, T., Tani, M., et al. (2015) Random-ized Phase II/III Clinical Trial of Elpamotide for Patients with Advanced Pancreatic Cancer: PEGASUS-PC Study. Cancer Science, 106, 883-890. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Samson, A., Bentham, M.J., Scott, K., et al. (2018) Oncolytic Reovirus as a Combined Antiviral and Anti-Tumour Agent for the Treatment of Liver Cancer. Gut, 67, 562-573. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Lichty, B.D., Breitbach, C.J., Stojdl, D.F. and Bell, J.C. (2014) Going Viral with Cancer Immunotherapy. Nature Reviews Cancer, 14, 559-567. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Noonan, A.M., Farren, M.R., Geyer, S.M., et al. (2016) Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Molecular Therapy, 24, 1150-1158. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Hirooka, Y., Kasuya, H., Ishikawa, T., et al. (2018) A Phase I Clinical Trial of EUS-Guided Intratumoral Injection of the Oncolytic Virus, HF10 for Unresectable Locally Advanced Pancreatic Cancer. BMC Cancer, 18, Article No. 596. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Habtetsion, T., Ding, Z.C., Pi, W., et al. (2018) Alteration of Tumor Metabolism by CD4+ T Cells Leads to TNF-α- Dependent Intensification of Oxidative Stress and Tumor Cell Death. Cell Metabolism, 28, 228-242. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Kondo, H., Hazama, S., Kawaoka, T., et al. (2008) Adoptive Immunotherapy for Pancreatic Cancer Using MUC1 Peptide-Pulsed Dendritic Cells and Activated T Lymphocytes. Anticancer Research, 28, 379-387.
|
|
[41]
|
Santos do Carmo, F., Ricci-Junior, E., Cerqueira-Coutinho, C., et al. (2016) Anti-MUC1 Nano-Aptamers for Triple- Negative Breast Cancer Imaging by Single-Photon Emission Computed To-mography in Inducted Animals: Initial Considerations. International Journal of Nanomedicine, 12, 53-60. [Google Scholar] [CrossRef]
|